Practically, the only other short-listed intervention (Table 5) that could readily be tested in a phase-3 platform for cSVD is one of the licensed oral AD drugs, as identified for VCI.40 Eight short-term small-to-medium sized trials of AChE-i have been performed in VaD and they showed efficacy with an odds ratio (1.52) which exceeds the platform target odds ratio of 1.4;41 the lower 95% CI boundary (1.36) just misses this. This evidence concerns the gene ACHE and Alzheimer disease.